These data collectively demonstrate that acriflavine suppresses TROP2‐high CRC liver metastatic colonisation and progression by disrupting the TROP2/YBX1/HIF‐1α/H3K18la signalling axis, suggesting its potential as a promising therapeutic strategy for TROP2‐high colorectal cancer. This evidence concerns the gene TACSTD2 and colorectal cancer.